Abbott adds colorectal cancer blood test to Cologuard portfolio after Freenome FDA win

Freenome, Inc. (Nasdaq: FRNM) has converted its first regulatory approval into an immediate financial and commercial catalyst, securing a $100 million payment from Abbott Laboratories (NYSE: ABT) only days after beginning public trading. Abbott plans to launch Freenome’s SimpleScreen CRC colorectal cancer blood test in the United States during fall 2026, adding the product to the cancer-screening business it expanded through the acquisition of Exact Sciences. The approval gives Freenome its first revenue-generating product while strengthening a balance sheet already supported by approximately $310 million raised through its Nasdaq transaction. For Abbott, the test creates a blood-based alternative alongside its established stool-based screening portfolio and could help reach adults who remain overdue for colorectal cancer screening. The commercial opportunity will depend on whether that convenience attracts previously unscreened patients, because SimpleScreen CRC detects most established cancers but misses the majority of advanced precancerous lesions.

Why the SimpleScreen CRC approval immediately strengthens Freenome’s newly public balance sheet

The FDA decision represents Freenome’s first approved commercial product and converts years of clinical development into an immediate cash milestone. Abbott is required to pay Freenome $100 million because the first-generation SimpleScreen CRC test achieved FDA approval for first-line colorectal cancer screening. The payment is particularly meaningful because Freenome began trading on the Nasdaq Capital Market under the ticker $FRNM on July 21, only six days before announcing the approval.

Freenome entered the public market through a business combination with Perceptive Capital Solutions Corp. The transaction generated approximately $310 million in gross proceeds, including roughly $70 million from the special-purpose acquisition company’s trust account and a $240 million private investment led by Perceptive Advisors and RA Capital. Adding the Abbott milestone gives Freenome a larger financial cushion as it prepares for commercialization, funds laboratory operations and develops additional cancer-screening products.

The broader commercialization agreement was originally signed with Exact Sciences in August 2025 and transferred to Abbott after Abbott completed its acquisition of Exact Sciences on March 23, 2026. The arrangement could provide Freenome with up to $885 million through upfront consideration, equity investment, research funding, regulatory milestones and potential guideline-related payments. It also includes royalties that are expected to rise toward 10% of test sales once specified gross-margin targets are reached.

Freenome had already received a $75 million upfront payment and a $50 million equity investment under the original agreement. The newly triggered $100 million FDA milestone is one component of up to $200 million tied to approval of the first-generation test and a future version. Another potential $500 million depends on achieving a qualifying A or B recommendation in future United States Preventive Services Task Force guidelines, making reimbursement and guideline placement central to the deal’s remaining value.

The agreement gives Abbott exclusive United States commercial rights to SimpleScreen CRC when used as a standalone colorectal cancer test. Freenome retained rights to use the colorectal component when it is combined with screening for additional cancers, preserving its ability to build a broader multi-cancer platform rather than becoming solely dependent on royalties from one product.

That structure separates the companies’ responsibilities. Abbott will lead market access, physician outreach and patient-support activities, while Freenome will initially handle laboratory processing, data analysis and return of results. Freenome can therefore benefit from national commercialization without immediately building a sales organization comparable with Abbott’s inherited Exact Sciences operation.

The approval also changes how investors may assess Freenome. Before July 27, the company’s valuation depended heavily on regulatory expectations, pipeline assumptions and its available capital. It now has an approved product, an expected fall launch, a $100 million payment and a commercial partner with an established colorectal cancer franchise.

How Abbott can use Cologuard infrastructure to accelerate a blood-test launch this fall

Abbott gained a major cancer diagnostics platform through its acquisition of Exact Sciences. That portfolio includes Cologuard, Cologuard Plus, the Cancerguard multi-cancer test and precision-oncology products used to guide or monitor treatment. SimpleScreen CRC adds a blood-based format to Abbott’s existing colorectal cancer offering rather than requiring the company to enter the market from the beginning.

When the original Freenome agreement was signed, Exact Sciences reported commercial connections with nearly 400 electronically integrated health systems, more than 865 in-network payers and more than 260,000 ordering physicians. It also had relationships with millions of patients who had previously been prescribed Cologuard. Abbott can now use that infrastructure to identify eligible patients, place orders through existing workflows, support insurance authorization and encourage completion of follow-up colonoscopy after a positive result.

This creates a portfolio strategy rather than a simple product substitution. Cologuard requires a patient to collect and return a stool sample, while SimpleScreen CRC requires two tubes of blood collected during a clinical visit. Some patients may prefer stool-based testing at home, while others may be more likely to complete screening when it can be added to a routine blood draw.

Owning access to both formats may allow Abbott to capture patients with different preferences instead of losing individuals who reject one specific screening method. The company can position Cologuard as a more prevention-oriented noninvasive option while offering SimpleScreen CRC to adults who remain unwilling to complete stool collection or colonoscopy.

The blood test’s commercial value therefore depends heavily on incremental screening. If SimpleScreen CRC primarily shifts patients away from Cologuard, Abbott may redistribute revenue within its own portfolio without greatly expanding the total market. The stronger outcome would involve bringing previously unscreened adults into the system and then converting positive blood-test results into completed colonoscopies.

Freenome and Abbott estimate that up to 60 million Americans are overdue for colorectal cancer screening. Even modest penetration could create meaningful testing volume, but the estimate does not represent an immediately addressable customer base. Eligibility, insurance coverage, physician adoption, laboratory capacity and willingness to undergo follow-up colonoscopy will all reduce the realistically accessible population.

Medicare coverage should reduce one major barrier. Updated national coverage criteria generally cover eligible noninvasive colorectal cancer biomarker tests once every three years when they are FDA-authorized, processed in a certified laboratory and meet required performance thresholds. SimpleScreen CRC’s reported 81.1% cancer sensitivity and 90.4% specificity place it above the applicable Medicare threshold requiring at least 79% sensitivity and 90% specificity.

Coverage does not guarantee rapid revenue. Abbott must obtain appropriate coding and reimbursement implementation, educate physicians, support sample logistics and ensure that the fall launch operates smoothly across health systems. Freenome must also demonstrate reliable laboratory turnaround and maintain quality as testing volume increases.

The $100 million milestone gives Freenome cash before commercial demand is established, while Abbott assumes much of the market-development burden. This reduces Freenome’s launch risk but also means its long-term economics will depend on royalty revenue and future milestones rather than retaining the full selling price of each test.

Why low precancer sensitivity remains the biggest commercial constraint on SimpleScreen CRC

SimpleScreen CRC was validated in PREEMPT CRC, a prospective study that enrolled more than 48,000 asymptomatic, average-risk adults across more than 200 sites. In a prespecified analysis adjusted to reflect the United States population, the test demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. It detected 13.7% of advanced precancerous lesions and 30.7% of precancerous lesions containing high-grade dysplasia.

The cancer-detection result is sufficient for FDA approval and Medicare access, but the precancer figure creates the product’s most important competitive limitation. Colorectal cancer screening can prevent disease when colonoscopy identifies and removes precancerous polyps before they become malignant. A blood test that misses most advanced precancerous lesions functions more effectively as a cancer-detection tool than as a cancer-prevention tool.

Stage 1 performance also matters because early diagnosis produces the greatest treatment advantage. The original commercial agreement disclosed Stage 1 sensitivity of 63.5% for the first-generation test. That result means a negative blood test cannot rule out early cancer, reinforcing the need for repeat screening and careful communication about the test’s limitations.

Freenome is already developing an updated version. July 2026 results showed that the modified assay and algorithm improved advanced precancerous lesion sensitivity to 18.2% and high-grade dysplasia sensitivity to 41.9%, while producing 80.4% colorectal cancer sensitivity and 90% specificity. The company intends to pursue supplemental FDA approval for that version, which could trigger another milestone under the Abbott agreement.

Those improvements are commercially useful but remain incremental. The updated test still missed most advanced precancerous lesions in the validation analysis, and Abbott’s initial fall launch will be based on the currently approved version rather than the unapproved next-generation assay.

SimpleScreen CRC will also compete with Guardant Health’s Shield, which became the first FDA-approved primary blood-based colorectal cancer screening test in 2024. Shield reported 83% colorectal cancer sensitivity and approximately 90% specificity in its pivotal study, placing the two products within a similar overall performance range.

The principal difference may therefore emerge through commercialization rather than headline sensitivity. Abbott has extensive physician, payer and patient relationships from Cologuard, while Freenome’s test uses two blood tubes and is expected to return results in about two weeks. Guardant Health has a head start in the blood-screening category, but Abbott can launch SimpleScreen CRC through infrastructure already built for population-level colorectal cancer screening.

Pricing will become another decisive factor, although the companies have not disclosed the planned United States list price. Abbott must balance adoption with reimbursement economics while accounting for Freenome’s royalty rights, laboratory-processing costs, physician support and patient navigation.

What investors should watch after Freenome’s FDA win and its first week on Nasdaq

Freenome shares were trading near $11.40 late Monday morning, up approximately 1.4% from the previous close after reaching an intraday high of $12.74. The initial reaction suggests investors welcomed the approval and $100 million milestone, although the stock gave back part of its earlier gain as trading progressed. Abbott shares were up approximately 2% at $105.14, but the SimpleScreen CRC approval represents only one development within a company valued at more than $180 billion.

The most immediate Freenome catalyst is execution of the fall commercial launch. Investors will be watching the timing of initial availability, insurance access, testing volume, laboratory turnaround and evidence that Abbott can reach patients who were not previously completing screening.

Royalty revenue may take time to become financially material. Freenome must first move from launch preparation to consistent order volume, while Abbott must integrate the test into its cancer diagnostics organization following the Exact Sciences acquisition. The economics will also depend on test pricing, reimbursement and gross margin, because the royalty rate is designed to increase as specified margin thresholds are achieved.

The next-generation assay creates a second regulatory catalyst. Supplemental approval could improve Freenome’s competitive profile and produce another payment, but the company must demonstrate that the updated version is reliable and clinically meaningful rather than relying solely on modest improvements in precancer detection.

Future guideline positioning carries even greater financial importance. Up to $500 million of the original deal is connected to a qualifying United States Preventive Services Task Force recommendation. That outcome could take years and will depend on evidence that blood-based screening improves participation and health outcomes, not merely on analytical accuracy.

Abbott’s strategic challenge is different. The company paid for Exact Sciences to establish a larger cancer diagnostics business and now needs to show that the platform can produce sustained growth. Abbott reported double-digit Cologuard growth during the first quarter of 2026, while the Exact Sciences acquisition contributed to a broader cancer diagnostics portfolio that also includes multi-cancer detection and precision-oncology products.

Abbott recently reaffirmed comparable sales-growth guidance of 6.5% to 7.5% for 2026 and raised its adjusted earnings-per-share outlook to between $5.45 and $5.60. SimpleScreen CRC is unlikely to materially change those figures during its partial-year launch, but it provides another product through which Abbott can justify the strategic logic of the Exact Sciences acquisition.

For Freenome, the approval is transformational because it reduces regulatory uncertainty and supplies immediate capital shortly after the public listing. For Abbott, it is a portfolio expansion that may help the company reach adults who reject its stool-based option. The long-term value will depend on whether a convenient blood draw expands total screening participation rather than simply moving existing patients from one noninvasive test to another.

Key takeaways from Freenome’s FDA approval and Abbott commercialization deal

• Freenome secured its first FDA-approved product only six days after beginning Nasdaq trading, giving the newly public company an unusually rapid transition from listing to commercial-stage diagnostics.
• The approval triggers a $100 million Abbott payment, adding to approximately $310 million in gross proceeds generated through Freenome’s business combination and private financing.
• The wider Abbott agreement could be worth up to $885 million, but much of that value depends on future assay approval, commercial performance and guideline placement that have not yet been achieved.
• Abbott will launch SimpleScreen CRC in fall 2026 using commercial infrastructure inherited through its March acquisition of Exact Sciences, including established Cologuard relationships.
• The blood test gives Abbott a second noninvasive colorectal cancer format, allowing it to serve patients who prefer a routine blood draw over stool collection.
• SimpleScreen CRC detected 81.1% of colorectal cancers with 90.4% specificity, enabling it to meet current Medicare performance requirements for eligible patients.
• Its 13.7% sensitivity for advanced precancerous lesions remains a major weakness because it limits the test’s ability to prevent cancer by identifying removable polyps.
• Freenome’s updated assay improved precancer detection, but that version is not included in the current FDA approval and will require a supplemental submission.
• Guardant Health’s Shield already competes in the blood-based screening category, making Abbott’s distribution scale and payer access central to SimpleScreen CRC’s commercial differentiation.
• The next investment test is whether Abbott can generate incremental screening among previously unscreened adults rather than merely shifting patients away from Cologuard or other established methods.